# N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

> **NCT05445882** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Bintrafusp alfa
- **DRUG:** N-803
- **BIOLOGICAL:** BN-Brachyury

## Key facts

- **NCT ID:** NCT05445882
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-04-01
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Closed by study team, no subjects enrolled.
- **Last updated:** 2024-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445882, "N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05445882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*